Life Sciences M&A: Pharma Milestone Snapshot

by Don Morrissey, Head of Life Sciences

Send us an email

Our new infographic provides a unique view into milestone achievement and new drug successes for biotech/pharma transactions with over $50MM upfront deal value. Built from the SRS Acquiom database of over 130 life sciences deals with more that $24 billion in potential milestone payments (from private-target life sciences M&A transactions from 2008 to 2017), this snapshot from our 2017 SRS Acquiom Life Sciences M&A Study will provide insight into common topics including:

Developmental Milestone Achievement by Product Phase
Early Stage Success Rate
Late Stage Success Rate

Don Morrissey Head of Life Sciences Mergers and Acquisitions M&A

About the author Don Morrissey Head of Life Sciences 720.279.0967

Don advises life science clients on M&A deal negotiations and post-closing milestones and earnouts. He is principal author of our life science studies and a frequent speaker at industry events. Before joining SRS Acquiom, Don spent more than a decade helping to grow two venture-backed life science start-up companies through IPOs. He has been responsible for many strategic transactions involving licensing, partnering and M&A, as well as financings with leading venture capital and private equity firms. He was formerly SVP, Corporate Development and General Counsel for Replidyne, an antibiotic drug development company, and VP, Legal Affairs and Business Development for Caliper Life Sciences, a microfluidics company. He began his career as a business attorney with Cooley LLP. Don holds a law degree from USC and a BA in Molecular, Cellular and Developmental Biology from the University of Colorado.